Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vabysmo

- PMLiVE

Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting

The company will present 90 abstracts from across a wide range of haematologic diseases, including results from three pivotal studies in lymphoma and haemophilia

- PMLiVE

UK’s NICE recommends Roche’s Evrysdi

The first oral therapy for the leading genetic cause of death among babies and young children will be available to 1,500 people in England after Roche signed a price-cutting deal

- PMLiVE

Roche and Novartis part ways with share purchase

Novartis is to sell its one-third stake in Roche for more than $20bn, paving the way for potential acquisitions

- PMLiVE

New data shows Roche’s Enspryng significantly reduces neuromyelitis optica spectrum disorder relapses

Enspryng is the first and only NMOSD treatment administered subcutaneously every four weeks

Roche Basel Switzerland

New data for Tecentriq in early-stage lung cancer

Roche’s PD-L1 blocker reduced the risk of disease recurrence and death for patients with stage 2-3a non-small cell lung cancer following surgery

Roche Basel Switzerland

Roche expands infectious disease test portfolio

PCR test specialist TIB Molbiol will join Roche to bolster its molecular diagnostics solutions for infectious diseases

Roche Basel Switzerland

Roche expands infectious disease test portfolio

PCR test specialist TIB Molbiol will join Roche to bolster its molecular diagnostics solutions for infectious diseases

Roche Basel Switzerland

Roche bets on T-cell therapies with Adaptimmune deal

Genentech signs deal for five ‘off the shelf’ T-cell therapies and a personalised cell therapy platform in a deal potentially worth more than $3bn

Roche Basel Switzerland

Tecentriq withdrawn in hard-to-treat breast cancer in US

A post-marketing study failed to show benefit for patients with triple-negative breast cancer taking Tecentriq and chemotherapy

- PMLiVE

EC approves BMS cell therapy for multiple myeloma

The approval of Abecma is based on “rapid, deep and durable” trial responses

Roche Basel Switzerland

FDA approval for Roche diagnostic solid tumour test

Test will identify which patients could benefit from GSK immunotherapy.

Roche Basel Switzerland

FDA approval for Roche diagnostic solid tumour test

Test will identify which patients could benefit from GSK immunotherapy.

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links